Literature DB >> 26016463

Twist in hepatocellular carcinoma: pathophysiology and therapeutics.

Hui Zou1, Xing Feng, Jian-Guo Cao.   

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related disease worldwide. Although HCC is mainly associated with viral hepatitis and alcoholic cirrhosis, numerous physiological and biochemical events are associated with HCC progression. The transcription factor Twist, which plays a key role in epithelial to mesenchymal transition, is reported to be associated with HCC. Overexpression of Twist causes various biochemical changes, such as increase of cell proliferation, reduction of apoptosis, cell cycle deregulation, generation of hepatic cancer stem cells, and in some cases, drug resistance. These changes result in various physiological changes, such as angiogenesis, cellular migration and invasion, and vasculogenic mimicry, which ultimately causes hepatocellular metastasis. Interestingly, targeting Twist via different strategies, especially small RNA technology, has shown promising therapeutic potential for future HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26016463     DOI: 10.1007/s12072-015-9634-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  65 in total

1.  HBx-dependent activation of Twist mediates STAT3 control of epithelium-mesenchymal transition of liver cells.

Authors:  Jing Teng; Xiaoqian Wang; Zhenxing Xu; Nanhong Tang
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

2.  Expression of twist and wnt in human breast cancer.

Authors:  Osamu Watanabe; Hiroshi Imamura; Tadao Shimizu; Jun Kinoshita; Toshihiro Okabe; Akira Hirano; Kazuhiko Yoshimatsu; Soichi Konno; Motohiko Aiba; Kenji Ogawa
Journal:  Anticancer Res       Date:  2004 Nov-Dec       Impact factor: 2.480

3.  Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.

Authors:  Terence K Lee; Ronnie T P Poon; Anthony P Yuen; Ming Tat Ling; Wei Kei Kwok; Xiang Hong Wang; Yong Chuan Wong; Xin Yuan Guan; Kwan Man; King Lok Chau; Sheung Tat Fan
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

4.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

Review 5.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.

Authors:  Mary Maluccio; Anne Covey
Journal:  CA Cancer J Clin       Date:  2012-10-15       Impact factor: 508.702

Review 6.  [Epithelial-mesenchymal transition in cancer progression].

Authors:  Monika Gos; Joanna Miłoszewska; Małgorzata Przybyszewska
Journal:  Postepy Biochem       Date:  2009

7.  Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer.

Authors:  Eelke H Gort; Karijn P M Suijkerbuijk; Suzan M Roothaan; Venu Raman; Marc Vooijs; Elsken van der Wall; Paul J van Diest
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

Review 8.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer.

Authors:  Mousumi Tania; Md Asaduzzaman Khan; Junjiang Fu
Journal:  Tumour Biol       Date:  2014-06-02

9.  Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.

Authors:  Aruljothi Subramaniam; Muthu K Shanmugam; Tina H Ong; Feng Li; Ekambaram Perumal; Luxi Chen; Shireen Vali; Taher Abbasi; Shweta Kapoor; Kwang Seok Ahn; Alan Prem Kumar; Kam M Hui; Gautam Sethi
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

10.  Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.

Authors:  Imogen Locke; Zsofia Kote-Jarai; Mary Jo Fackler; Elizabeth Bancroft; Peter Osin; Ashutosh Nerurkar; Louise Izatt; Gabriella Pichert; Gerald P H Gui; Rosalind A Eeles
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  5 in total

Review 1.  Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma.

Authors:  Na Li; Ying Zhu
Journal:  Therap Adv Gastroenterol       Date:  2019-01-22       Impact factor: 4.409

2.  KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.

Authors:  Jihua Han; Fengyue Wang; Yaliang Lan; Jiabei Wang; Chunlei Nie; Yingjian Liang; Ruipeng Song; Tongsen Zheng; Shangha Pan; Tiemin Pei; Changming Xie; Guangchao Yang; Xirui Liu; Mingxi Zhu; Yan Wang; Yao Liu; Fanzheng Meng; Yifeng Cui; Bo Zhang; Yufeng Liu; Xianzhi Meng; Jiewu Zhang; Lianxin Liu
Journal:  Oncogene       Date:  2018-08-16       Impact factor: 9.867

3.  The Characteristics and Mortality of Chinese Herbal Medicine Users among Newly Diagnosed Inoperable Huge Hepatocellular Carcinoma (≥10 cm) Patients: A Retrospective Cohort Study with Exploration of Core Herbs.

Authors:  Shu-Ling Chen; Chia-Ying Ho; Wei-Chun Lin; Chao-Wei Lee; Yu-Chun Chen; Jiun-Liang Chen; Hsing-Yu Chen
Journal:  Int J Environ Res Public Health       Date:  2022-09-30       Impact factor: 4.614

Review 4.  The relationship between vasculogenic mimicry and epithelial-mesenchymal transitions.

Authors:  Qiqi Liu; Lili Qiao; Ning Liang; Jian Xie; Jingxin Zhang; Guodong Deng; Hui Luo; Jiandong Zhang
Journal:  J Cell Mol Med       Date:  2016-03-29       Impact factor: 5.310

5.  PSMC5 Promotes Proliferation and Metastasis of Colorectal Cancer by Activating Epithelial-Mesenchymal Transition Signaling and Modulating Immune Infiltrating Cells.

Authors:  Zirui He; Xiao Yang; Ling Huang; Leqi Zhou; Sen Zhang; Jing Sun; Minhua Zheng; Junjun Ma; Bo Feng; Lu Zang
Journal:  Front Cell Dev Biol       Date:  2021-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.